Preemptive combined preventive delivery of flurbiprofen axetil produced effective analgesia after lumpectomy
FuZhou Wang,XiaoFeng Shen,ShiQin Xu,Li Ma,YuSheng Liu,ShanWu Feng,QingSong Zhao,LiPing Zhao
DOI: https://doi.org/10.1016/j.acpain.2008.03.002
2008-01-01
Acute Pain
Abstract:Methods Four hundred ASA I–II patients, undergoing lumpectomy, were screened and 236 were randomly assigned into one of two groups ( n = 118). In the flurbiprofen group, patients received an i.v. injection of flurbiprofen 50 mg 15 min before the start and the end of the operation, separately. The placebo group received the same volumes of saline before the start and the end of the operation. The Visual Analog Scale (VAS) pain intensity at rest, overall satisfaction score, additional morphine consumption and side effects were recorded. Results A total of 196 patients completed the study. Subjects received flurbiprofen experienced significant pain relief and improvement of the feeling of satisfaction at the first 24 h after surger. The additional morphine was consumed [8.5 mg (95% CI 4.2–12.4) in the saline group vs. 1.1 mg (95% CI 0.7–2.5) in the flurbiprofen group, p = 0.046]. No intergroup difference was observed in the incidence of side effects. Conclusion Preemptive combined preventive administration of flurbiprofen axetil showed effective analgesia significantly up to 24 h after lumpectomy and suggested it is a reliable analgesic for acute postoperative pain therapy. Keywords Pain, Postoperative Analgesia Anti-inflammatory agents, Non-steroidal Mastectomy, Segmental Flurbiprofen 1 Introduction When the pharmacological effects of anaesthetics fade away after the anaesthesia, the area of the lumpectomy can recover some of its senses, which can cause mild discomfort in the breast, and the pain improves slowly and can linger for a long time [1] . In general, benign breast masses were excised under local anaesthesia in the day-surgical department with less treatment of the pain from breast incision. While several reports concerned the postoperative pain management after breast surgeries, they merely focussed on the nerve blocking methods [2,3] . In contrast to this, little information is available about the bolus injection of analgesics intravenously (i.v.) referring to post-surgical analgesia in excision of breast masses. Preemptive analgesia is defined as an antinociceptive treatment that prevents establishment of altered central processing of afferent input from injuries [4] . This can effectively prevent earlier onset of the pain than that of the preventive administration of the drugs after surgical procedures, but it was controversial whether preemptive or preventive analgesia should be used to describe the difference between the two analgesic techniques [5–7] . Nevertheless, in this study we still adapted the concepts of preemptive analgesia delivering drugs before operation and preventive analgesia delivering drugs intraoperatively. The analgesic action of non-steroidal anti-inflammatory drugs (NSAIDs) has been explained on the basis of the inhibition of the enzymes that synthesize prostaglandins [8] . Flurbiprofen axetil is a member of the phenylalkanoic acid derivative family of NSAIDs, and exerts potent function of anti-inflammation and antinociception after i.v. administration [9,10] . Preemptive administration of flurbiprofen was advised as a preferred delivery manner for postoperative pain management after some surgical procedures [11,12] . 50 mg flurbiprofen administered before operation suppressed immediate postoperative pain; however, the analgesic effect disappeared in a few hours and was insufficient for overnight pain relief [13] . Therefore, we hypothesized that a combination of preemptive and preventive flurbiprofen would be a superior method for longer postoperative pain relief than the single delivery of the drug preemptively. The aim of this study was to objectively evaluate the analgesic efficacy of flurbiprofen axetil administrated preemptively combined with preventive injection by using the 100-mm chiroscience gauge of Visual Analog Scale (VAS) after lumpectomy. 2 Materials and methods 2.1 Participants and ethics With the Hospital Ethics Examining Committee of Human Research approval 400 ASA physical status I–II patients who underwent elective lumpectomy were screened, and 236 of them were enrolled in this randomised, follow-up, double-blind and controlled study. All participants signed an informed consent and a full explanation was given about flurbiprofen axetil, the general anaesthesia and the linear VAS of pain and satisfaction. 2.2 Exclusion criteria Patients were excluded from the study if one or more of the following criteria were met: (1) allergy to opioids, a history of the use of centrally acting drugs of any sort, chronic pain and psychiatric diseases records; (2) participants younger than 18 years or older than 65 years or with pregnancy; (3) those who were not willing to or could not finish the whole study at any time; (4) the post-anaesthetic care unit (PACU) assessing score was under 6 on a scale of 10 (measuring somnolence, respiration, movement, colour, and blood pressure on 0–2 scales), and arterial oxygen saturation measured by pulse oximetry (SaO 2 ) was 92% or lower (supplemental oxygen was permitted); (5) using or used in the past 14 days the monoamine oxidase inhibitors; (6) alcohol addictive or narcotinum-dependent patients were excluded for their influence on the analgesic efficacy of the study substance; (7) subjects with gastrointestinal ulcers and asthma, or receiving therapy with quinolone antibiotics. 2.3 Study design All enrolled patients were randomly assigned into one of two groups according to SNOSE way [14] : placebo group (saline, S) and flurbiprofen group (flurbiprofen axetil, F). The drug was injected in the volume of 5 ml contained 50 mg flurbiprofen 15 min before the operation and 50 mg 15 min before the end of the surgeries. The placebo group received the same volume of saline, and delivered, respectively, 15 min before the start and the end of the operation. The randomised opaque envelopes were kept closed until 15 min before the operation started. All research staff, data collection doctors and nurses, and drug delivery personnel were kept away from the contents of the brown syringe except for the drug numbers, No. 1, or No. 2 for each time (differing in drug allocation each time), until the end of the whole study. The corresponding drug name and number were sealed in an envelope and kept in the Science & Education Department of our hospital. Each syringe was filled with saline or flurbiprofen axetil from similar brown ampoule with the same volume. We used brown syringe and ampoule mainly for keeping the contents away from the study investigators because of the characteristic of flurbiprofen axetil in a white microemulsion manner. Baseline measurements of pain were recorded immediately before transferring to surgical wards. The study drug was administered as a 5 ml bolus over 20–30 s, followed by a continuous follow-up up to 24 h. Additional drugs were not allowed except for 0.04 mg/kg morphine delivered via an intravenous patient-controlled analgesic (PCA) pump (with a bolus of morphine 0.04 mg/kg, a lockout interval of 30 min) as rescue drug for uncontrolled pain. Ondansetron 0.15 mg/kg was administrated prophylactically, but patients still could receive metoclopramide 10 mg i.v. every 6 h administered at the discretion of the nursing staff. Diphenhydramine 25 mg i.v. was delivered for treating pruritus. Patients received supplemental oxygen therapy via nasal tube (40% O 2 2–4 l/min) after their return to the surgical wards to remain the SaO 2 above 92%. The parameters monitored during the whole study, from before the operation to the end of the study, included the measurement of heart rate by three-lead electrocardiograph, respiratory rate, noninvasive systolic and diastolic blood pressure, mean arterial pressure and fingertip pulse oximetry (Nihon Kohden, TL-201T, Tokyo, Japan). 2.4 Anaesthesia and perioperative management Total intravenous anaesthesia (TIVA) was performed in each patient. Sufentanil 0.20 μg/kg, midazolam 0.05 mg/kg and propofol 1.5–2.0 mg/kg were slowly injected i.v. for induction. The maintenance anaesthetics were propofol infused intraoperatively at a rate of 30–50 μg/(kg min), and remifentanil at a rate of 0.15 μg/(kg min). During the whole process of anaesthesia, spontaneous respiration was maintained, and artificial support was given timely if only the respiratory rate was lower than eight times per minute which was defined as the respiration depression. The pumping of propofol was stopped at about 10 min before the end of the operation, and remifentanil was stopped at approximately 5 min before the end of the surgery. No neuromuscular relaxants were used. All the participants underwent a mono-lateral single incision for the breast mass excision. A catheter was inserted in a right or left antecubital vein for fluid and drug administration. Intra- and postoperative fluid management included replacement of preexisting fluid deficits, normal losses (maintenance requirements), and surgical wound losses including blood loss, and the amount of urine collected via an indwelling urinary catheter, haemodynamic variables and haemoglobin concentration were measured. No additional drugs were administrated perioperatively except for the routine administration of atropine sulphate 8.0 μg/kg and phenobarbital sodium 1.5 mg/kg used intramuscularly 30 min prior to surgery. 2.5 Postoperative measures During the whole process of study, the patient-derived VAS scores of pain at rest and vital signs were recorded hourly from 1 h until 12 h after the surgical procedures and 6-hourly up to the 24th hour. Additional morphine consumption was calculated automatically by the PCA pump after pressing the delivery button each time, and the total morphine usage was recorded finally. An overall maximal pain intensity to each patient, namely the most severe affliction of pain the patient felt at the end of the 24-h study, was scored. Finally, the occurrence of the side effects throughout the study was recorded by the follow-up physicians. 2.6 Primary outcome The VAS ratings of pain at rest were measured with the 100-mm chiroscience gauge as reported previously [15] , as the primary outcome, i.e. subjective pain intensity score was established based on a 0–100 mm linear VAS (0 = no pain; 100 = worst pain imaginable). A VAS pain score of less than or equal to 30 was considered to represent effective analgesia. Patients were instructed that one end of the scale represented no impact of pain at all and the other end was representative of extreme or severe impact of it. 2.7 Secondary outcomes The following measures were selected as the secondary outcomes: (1) Overall subjective feeling of satisfaction, a 1–100 mm linear VAS used (1 = sad; 100 = happy). (2) Morphine consumption in the two groups was calculated and expressed with median and corresponding 95% confidence interval (95% CI). (3) Incidence of side effects. 2.8 Statistical analysis Analyses were performed using GraphPad Prism version 5.0 (GraphPad Software Inc., San Diego, CA, USA). Values are expressed as the mean, median, standard deviation (S.D.), 95% CI or numbers. A pre-study power table where δ (the mean difference in VAS pain scorings recorded in a pilot study) equalled 2.7 ± 1.1 in the S group and 1.8 ± 0.5 in the F group, α = 0.05 and power = 0.95, resulted in the need for a minimum of 10 patients in each group. The demographic data and background characteristics, the ASA physical status and morphine consumption were compared with two-way analysis of variance (ANOVA). The effects of the study drugs on patient's self-rated VAS of pain and satisfaction were analysed by two-way ANOVA with repeated measures. The ANOVA tests were always followed by the Bonferroni post hoc tests. Finally, a Chi-square t -test was performed to compare side effects between the two groups. Statistical significance was accepted at the level of p ≤ 0.05. 3 Results Fig. 1 shows the most common reasons for exclusion among the 400 patients who were screened but not enrolled, and the 236 patients who were randomly assigned to the two groups and followed up. Finally, 97 patients in saline group and 99 patients in flurbiprofen axetil group completed the whole study. The demographic, background, surgical, anaesthesia and intraoperative management data, baseline vital signs (all were within the physiological ranges throughout the anaesthesia and surgical process) were not significantly different between the two groups ( Table 1 ). Preemptive plus preventive administration of flurbiprofen axetil evidenced significant lower VAS scorings of pain at rest during the whole follow-up period than the saline group ( p < 0.05, Fig. 2 ), the average scoring was 1.1 ± 0.5 (×10 mm) in the F group vs. 4.2 ± 1.3 (×10 mm) in the S group ( Fig. 2 ). In addition, the overall intensity of pain was evaluated at the end of the study, and flurbiprofen axetil expressed significant lower scorings than that of the saline group ( p < 0.0001, Fig. 3 ). Additional morphine was delivered timely if the patients were under inefficient analgesia and the total morphine consumption was calculated. Flurbiprofen axetil-treated subjects consumed less morphine than the saline one ( p = 0.046, Table 2 ). Patients’ overall feeling of satisfaction was better in the F group than the S group ( p = 0.005, Table 2 ). The incidence of different side effects was expressed in Table 3 . The total incidence of side effects in the F group and the S group expressed no significant difference. But specially, the mydriasis in flurbiprofen group was far more, approximately 30%, than the saline group ( Table 3 ). 4 Discussion The results of this study demonstrate that in combination of preemptive and preventive administration of flurbiprofen axetil produced effective analgesia and the overall intensity of pain was fluctuated between 1 and 2 points of level in the VAS scorings. In line with this, the additional morphine requirement was much less in the flurbiprofen-treated patients than the saline control one, and the patients in flurbiprofen axetil group experienced superior feeling of satisfaction than the saline group. However, no statistically significant difference was observed in the incidence of side effects between them. In the present study, we combined the drug-delivering manners administered preoperatively plus intraoperatively, and such manner expressed significant analgesia after lumpectomy. Premedication of drugs belongs to one of the prophylactic ways by suppressing potential nociceptive input from the surgical injuries before hand, but the intraoperative medication then is a complementary therapy for inhibiting the ongoing negative input and preventing the onset of postoperative pain. In the current study, the persistent effect over 1 day may be related to the readministration about 1 h after the initial dose, thereby providing a relative high initial dose of this drug coinciding with the interval of maximal nociceptive input for this short, minimally invasive surgical procedure. Flurbiprofen act via inhibiting the cyclooxygenase reversibly, resulting in corresponding anti-inflammatory effect and causing the peripheral inhibition of prostaglandin synthesis [16] . In addition, flurbiprofen plays a role by inhibiting the migration of leukocytes into sites of inflammation and preventing the formation of thromboxane A2, an aggregating agent, by the platelets [17–19] . Thus the anti-inflammatory and antinociceptive effects of flurbiprofen on postoperative pain was advised and recommended for preemptive administration to suppress the synthesis of prostaglandin prophylactically at the area of the surgical injuries, which in return relieve the pain from the surgical wound [10,20,21] . Consistent with these data, our results show that effective pain relief was provided by the premedication of flurbiprofen combined with intraoperative redosing in the context of breast masses excision. Administration of flurbiprofen axetil decreased the additional morphine consumption after lumpectomy. In line with this, the overall feeling of satisfaction was significantly improved. Thus we recommend that flurbiprofen axetil 50 mg can be used 15 min before the start and the end of lumpectomy, respectively, for acute postoperative pain management. Incidence of side effects was one of the main concerns when processing a drug therapy. In the present study, the side effects in both groups were lower and similar except for the mydriasis in flurbiprofen. Pupil dilation effect of flurbiprofen was not a threatening side event which merely lasted 1–2 h and this effect was used as a positive part in the ophthalmological surgeries [22,23] . Therefore, flurbiprofen axetil as a single agent used as an antinociceptive and anti-inflammatory drug can be safely administrated in the surgery of breast mass excision. In conclusion, preemptive combined with preventive administration of flurbiprofen axetil is an effective way to produce significant analgesia up to 24 h after lumpectomy. Conflict of interest None. Acknowledgments We are indebted to Mrs. Cana Lee F. Laeno for her critical reading of the manuscript. We also thank Mrs. YuFeng Wang for her help in searching literatures. References [1] Surgery and Radiation Pain. http://www.breastcancer.org/tips/pain/canc_v_non/surg_rad.jsp?gclid=CLH82Iq3r5ACFRMvTAod8ztj5w [last accessed date: March 8, 2008]. [2] A. Dabbagh H. Elyasi The role of paravertebral block in decreasing postoperative pain in elective breast surgeries Med Sci Monit 13 10 2007 CR464 CR467 [3] S. Aida H. Baba T. Yamakura K. Taga S. Fukuda K. Shimoji The effectiveness of preemptive analgesia varies according to the type of surgery: a randomized, double-blind study Anesth Analg 89 3 1999 711 716 [4] I. Kissin Preemptive analgesia Anesthesiology 93 4 2000 1138 1143 [5] J. Katz C.J. McCartney Current status of preemptive analgesia Curr Opin Anaesthesiol 15 4 2002 435 441 [6] E.M. Pogatzki-Zahn P.K. Zahn From preemptive to preventive analgesia Curr Opin Anaesthesiol 19 5 2006 551 555 [7] R. Dionne Preemptive vs preventive analgesia: which approach improves clinical outcomes? Compend Contin Educ Dent 21 1 2000 48 51–4, 56 [8] J.N. Cashman The mechanisms of action of NSAIDs in analgesia Drugs 52 Suppl 5 1996 13 23 [9] J. Buritova J.M. Besson Peripheral and/or central effects of racemic-, S (+)- and R (−)-flurbiprofen on inflammatory nociceptive processes: a c-Fos protein study in the rat spinal cord Br J Pharmacol 125 1 1998 87 101 [10] M. Takada M. Fukusaki Y. Terao K. Yamashita C. Inadomi M. Takada Preadministration of flurbiprofen suppresses prostaglandin production and postoperative pain in orthopedic patients undergoing tourniquet inflation J Clin Anesth 19 2 2007 97 100 [11] K. Yamashita M. Fukusaki Y. Ando A. Fujinaga T. Tanabe Y. Terao Preoperative administration of intravenous flurbiprofen axetil reduces postoperative pain for spinal fusion surgery J Anesth 20 2 2006 92 95 [12] K. Mikawa K. Nishina N. Maekawa M. Shiga H. Obara Dose–response of flurbiprofen on postoperative pain and emesis after paediatric strabismus surgery Can J Anaesth 44 1 1997 95 98 [13] S. Nishiike T. Kato M. Nagai A. Nakagawa M. Konishi Y. Sakata Preoperative flurbiprofen for pain prevention after tonsillectomy in adults J Clin Anesth 19 8 2007 596 600 [14] G.S. Doig F. Simpson Randomization and allocation concealment: a practical guide for researchers J Crit Care 20 2 2005 191 193 [15] A.A. Weinbroum B. Bender A. Nirkin S. Chazan I. Meller Y. Kollender Dextromethorphan-associated epidural patient-controlled analgesia provides better pain- and analgesics-sparing effects than dextromethorphan-associated intravenous patient-controlled analgesia after bone-malignancy resection: a randomized, placebo-controlled, double-blinded study Anesth Analg 98 3 2004 714 722 [16] M. Basselin N.E. Villacreses H.J. Lee J.M. Bell S.I. Rapoport Flurbiprofen, a cyclooxygenase inhibitor, reduces the brain arachidonic acid signal in response to the cholinergic muscarinic agonist, arecoline, in awake rats Neurochem Res 32 11 2007 1857 1867 [17] R.G. McFadden M.A. Bishop A.N. Caveney L.J. Fraher Effect of platelet activating factor (PAF) on the migration of human lymphocytes Thorax 50 3 1995 265 269 [18] M. Bolla D. You L. Loufrani B.I. Levy S. Levy-Toledano A. Habib Cyclooxygenase involvement in thromboxane-dependent contraction in rat mesenteric resistance arteries Hypertension 43 6 2004 1264 1269 [19] J. Van Ryan-McKenna M.R. Buchanan Relative effects of flurbiprofen on platelet 12-hydroxy-eicosatetraenoic acid and thromboxane A2 production: influence on collagen-induced platelet aggregation and adhesion Prostaglandins Leukot Essent Fatty Acids 36 3 1989 171 174 [20] M. Nakayama H. Ichinose S. Yamamoto K. Nakabayashi O. Satoh A. Namiki Perioperative intravenous flurbiprofen reduces postoperative pain after abdominal hysterectomy Can J Anaesth 48 3 2001 234 237 [21] H. Aoki M. Satomoto S. Yamada Y. Adachi H. Higuchi E. Umeda The effectiveness of perioperative intravenous flurbiprofen in minor ear, neck and nose surgery Masui 51 8 2002 857 861 [Japanese] [22] R.H. Keates K.A. McGowan Clinical trial of flurbiprofen to maintain pupillary dilation during cataract surgery Ann Ophthalmol 16 10 1984 919 921 [23] H. Tabandeh J. McAlister G. Thompson Effect of flurbiprofen on acetylcholine-induced pupillary contraction Eur J Ophthalmol 5 3 1995 177 180